Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

German Reimbursement Decisions Will Remain Officially Opaque In New Law

This article was originally published in The Pink Sheet Daily

Executive Summary

Far from granting industry a greater say in German reimbursement decisions, amended laws appear to endorse their lack of transparency as a new system kicks in.

Advertisement

Related Content

Trajenta’s German Renaissance Nipped In The Bud; Revised Dossier Falls Short
Germany’s Pricing Revolution: Why The World Should Be Watching
Germany’s Added Benefit System May Gain Credibility As It Lauds Zytiga And Cans Trajenta
Germany’s Added Benefit System May Gain Credibility As It Lauds Zytiga And Cans Trajenta
Success Of German Cost-Control Law Raises Prospect Of Further Cuts For Pharma
Mediator Scandal Provokes Flurry of French Health Reforms But Impact Is Hard To Gauge Until The Dust Settles

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS073149

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel